|
Market Closed -
Australian S.E.
13:50:46 14/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.3700 AUD | -1.33% |
|
-1.33% | -43.08% |
| 07-30 | Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy | MT |
| 07-21 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| Market Cap | 111M 78.55M 67.84M 63.75M 57.98M 109M 7.51B 747M 292M 3.76B 295M 289M 12.5B | P/E 2026 * |
-6.07x | P/E 2027 * | -4.35x |
|---|---|---|---|---|---|
| Enterprise Value | 116M 82.26M 71.05M 66.76M 60.72M 114M 7.87B 782M 306M 3.94B 309M 302M 13.09B | EV / Sales 2026 * |
14.9x | EV / Sales 2027 * | 10.9x |
| Free-Float |
62.73% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.33% | ||
| 1 week | -1.33% | ||
| 1 month | -3.90% | ||
| 3 months | -21.28% | ||
| 6 months | -37.29% | ||
| Current year | -43.08% |
| 1 week | 0.37 |  | 0.38 |
| 1 month | 0.35 | | 0.39 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.74 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 31/7/26 | Buy | Chief Executive Officer | 25,000 | 0.0083% | ||
| 31/7/26 | Buy | Director | 75,000 | 0.0250% | ||
| 31/7/26 | Buy | Director | 37,500 | 0.0125% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.33% | -1.33% | -14.94% | -48.61% | 78.55M | |
| -2.25% | -0.47% | +72.43% | +119.36% | 1,052B | |
| -0.66% | +0.43% | +49.01% | +50.11% | 627B | |
| -0.54% | +1.39% | +21.88% | +63.83% | 441B | |
| -1.99% | -3.32% | +41.98% | +34.08% | 349B | |
| -1.05% | -2.81% | +24.22% | +34.67% | 287B | |
| -2.12% | -3.67% | -1.09% | +3.11% | 241B | |
| -0.63% | +1.04% | +43.03% | +59.10% | 224B | |
| -1.19% | -3.41% | -9.18% | -52.41% | 202B | |
| +0.16% | +3.87% | +16.25% | +73.27% | 172B | |
| Average | -0.73% | +0.26% | +24.36% | +33.65% | 359.53B | |
| Weighted average by Cap. | -0.09% | +0.32% | +41.31% | +62.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.51M 4.76M 4.48M 4.07M 7.65M 527M 52.44M 20.5M 264M 20.7M 20.26M 878M | 12.5M 8.86M 7.65M 7.19M 6.54M 12.29M 847M 84.24M 32.94M 424M 33.26M 32.54M 1.41B |
| Net income | -18.29M -12.97M -11.2M -10.52M -9.57M -18M -1.24B -123M -48.22M -621M -48.69M -47.63M -2.06B | -25.1M -17.79M -15.37M -14.44M -13.13M -24.69M -1.7B -169M -66.16M -852M -66.8M -65.35M -2.83B |
| Net Debt | 5.24M 3.71M 3.21M 3.01M 2.74M 5.15M 355M 35.29M 13.8M 178M 13.93M 13.63M 591M | 24.96M 17.7M 15.28M 14.36M 13.06M 24.56M 1.69B 168M 65.8M 847M 66.44M 65M 2.82B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/08/26 | A$0.3700 | -1.33% | 29,428 |
| 13/08/26 | A$0.3750 | 0.00% | 36,019 |
| 12/08/26 | A$0.3750 | -2.60% | 69,391 |
| 11/08/26 | A$0.3850 | 0.00% | 62,051 |
| 10/08/26 | A$0.3850 | +2.67% | 47,133 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
